Repligen (NASDAQ:RGEN) Rating Reiterated by Stephens

Stephens reiterated their overweight rating on shares of Repligen (NASDAQ:RGEN) in a research report sent to investors on Tuesday, Benzinga reports. Stephens currently has a $170.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Repligen from $230.00 to $200.00 and set an overweight rating on the stock in a research note on Thursday, May 2nd. Deutsche Bank Aktiengesellschaft upgraded Repligen from a hold rating to a buy rating and dropped their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, Guggenheim started coverage on Repligen in a research note on Tuesday, June 18th. They set a neutral rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $190.88.

Repligen Stock Down 2.4 %

Shares of Repligen stock opened at $161.67 on Tuesday. The business’s 50 day simple moving average is $134.92 and its 200 day simple moving average is $166.05. Repligen has a 52-week low of $110.45 and a 52-week high of $211.13. The firm has a market cap of $9.06 billion, a PE ratio of 646.71, a P/E/G ratio of 5.65 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.24 and a current ratio of 6.35.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same quarter last year, the firm earned $0.53 EPS. Repligen’s revenue for the quarter was down 3.2% compared to the same quarter last year. On average, analysts predict that Repligen will post 1.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other Repligen news, CEO Anthony Hunt sold 20,072 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the transaction, the chief executive officer now directly owns 163,177 shares of the company’s stock, valued at approximately $27,456,162.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 20,072 shares of the stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $168.26, for a total value of $3,377,314.72. Following the sale, the chief executive officer now directly owns 163,177 shares in the company, valued at $27,456,162.02. The disclosure for this sale can be found here. Insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after buying an additional 21,719 shares during the last quarter. Brown Capital Management LLC raised its position in Repligen by 5.8% in the fourth quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company’s stock valued at $274,207,000 after purchasing an additional 83,416 shares during the last quarter. Bank of New York Mellon Corp raised its position in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in Repligen by 31.5% in the first quarter. Principal Financial Group Inc. now owns 345,445 shares of the biotechnology company’s stock valued at $63,534,000 after purchasing an additional 82,737 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.